Securities Exchange Act of 1934

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

Retrieved on: 
Thursday, November 10, 2022

Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.

Key Points: 
  • Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.
  • For full year 2022, Prenetics raises revenue guidance to the range of US$270 million to US$280 million and raises full year adjusted EBITDA guidance to the range of US$47 million to US$53 million.
  • Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release.
  • An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."

EQS-News: Blend Is Building a Future Where Proactive Finance Revives the Primary Banking Relationship

Retrieved on: 
Friday, November 11, 2022

Thats why its developed a consumer banking platform that empowers banks to offer personalization, convenience and streamlined functionality to customers.

Key Points: 
  • Thats why its developed a consumer banking platform that empowers banks to offer personalization, convenience and streamlined functionality to customers.
  • Proactive finance is one of the latest trends in banking.
  • While this future of proactive delivery is still in development, lenders are already leveraging Blend to minimize tedious data entry and maximize operational efficiency.
  • That kind of cohesive and streamlined proactive banking experience, Blend says, is the key to rebuilding that primary banking relationship with customers.

IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor

Retrieved on: 
Thursday, November 10, 2022

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

Key Points: 
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs.
  • IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.
  • IntelGenx assumes no obligation to update any such forward-looking statements.

Wearable Devices and Trimble Showcase the Use of Neural Input Technology for Controlling the Spot Autonomous Robot

Retrieved on: 
Thursday, November 10, 2022

YOKNEAM ILLIT, ISRAEL and Westminster, Col., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Wearable Devices (Nasdaq: WLDS) (“Wearable Devices” or the “Company”) today announced that the Company showcased the usage of brain neural commands to operate Spot, the autonomous construction robotics solution, at the 2022 Trimble Dimensions+ Conference, held on November 7-9, 2022 in Las Vegas.

Key Points: 
  • At the conference, the operator was able to control aspects of the robots motion using neural input signals for discrete or continuous control.
  • "A new interaction paradigm is required to effectively merge the digital and physical environments, and we believe that neural input technology can play a major role in achieving this."
  • Wearable Devices Mudra technology provides hands-free and touch-free interaction of digital devices, robots and machines using the Mudra neural input wristband.
  • Wearable Devices Ltd. (the Company), a growth company developing a non-invasive neural input interface technology in the form of a wrist wearable band for controlling digital devices using subtle finger movements.

Trust Stamp Achieves Revenue Increase of 309% and Gross Profit Increase of 915% for Q3 2022

Retrieved on: 
Thursday, November 10, 2022

"Over the past two years, Trust Stamp has been working diligently to transition from the model we used with our early customers--building custom platforms and custom solutions--to a model that provides scalability and a SaaS revenue model. Our end-to-end Identity Orchestration Platform dramatically decreases integration time and increases client flexibility to tailor a Trust Stamp solution to meet their specific need, as well as opening access to a market that relies on low-code partner integrations. We are at an inflection point for our Orchestration Platform, as multiple customers are now using the platform. We are beginning to see exciting results, as our platform offers rapid deployment across devices and platforms, with custom workflows that seamlessly orchestrate trust across the identity lifecycle for a consistent user experience in processes for onboarding, including know-your-customer (KYC) and anti-money laundering (AML) regulations, multi-factor authentication, account recovery, fraud prevention, compliance, and more.”

Key Points: 
  • Gareth Genner, Chief Executive Officer, comments, We achieved a 309% year-over-year increase in revenue and a 915% increase in gross profit for Q3 2022, as well as a 208% increase in revenue and 354% in gross profit for the nine months ended September 30, 2022.
  • Net revenue increased by $1.02 million or 308.5%, to $1.35 million for Q3 2022, compared to $330 thousand for Q3 2021.
  • Gross profit increased by $739 thousand or 914.8% for Q3 2022 compared to the same period last year, and gross profit margin improved to 60.8% for Q3 2022, compared to 24.5% for Q3 2021.
  • Research and development (R&D) costs for Q3 2022 were $778 thousand for Q3 2022, compared to $579 thousand for Q3 2021.

Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Thursday, November 10, 2022

BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.

Key Points: 
  • BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.
  • Collaboration revenues for the quarter ended September 30, 2022 were $0.8 million, compared to $1.7 million for the quarter ended September 30, 2021.
  • Research and development expenses for the quarter ended September 30, 2022 were $25.9 million, compared to $24.0 million for the quarter ended September 30, 2021.
  • General and administrative expenses for the quarter ended September 30, 2022 were $7.8 million, compared to $8.4 million for the quarter ended September 30, 2021.

Compass Minerals International, Inc. (CMP) Equity Alert: If You Suffered a Significant Loss in Compass Minerals International, Inc. Contact Robbins LLP for Information About Your Rights

Retrieved on: 
Thursday, November 10, 2022

What Now: Similarly situated shareholders may be eligible to participate in the class action against Compass Minerals.

Key Points: 
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Compass Minerals.
  • Shareholders who want to be appointed lead plaintiff for the class must file their papers by December 20, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • Following this announcement, the price of Compass Minerals stock declined by more than 30% over the following two days.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022

Retrieved on: 
Thursday, November 10, 2022

The Company has scheduled a conference call the next morning, Tuesday, November 22, 2022, at 9:00 AM ET to review its third quarter financial results.

Key Points: 
  • The Company has scheduled a conference call the next morning, Tuesday, November 22, 2022, at 9:00 AM ET to review its third quarter financial results.
  • Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET.
  • The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Monday, November 21, 2022.
  • The Company anticipates no change to the preliminary sales results for the third quarter of 2022 that were disclosed on October 5, 2022.

International Game Technology PLC (IGT) Class Action: If You Suffered a Significant Loss in International Game Technology PLC Contact Robbins LLP for Information About Your Rights

Retrieved on: 
Thursday, November 10, 2022

What Now: Similarly situated shareholders may be eligible to participate in the class action against IGT.

Key Points: 
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against IGT.
  • Shareholders who want to be appointed lead plaintiff for the class must file their papers by December 13, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • You do not have to participate in the case to be eligible for a recovery.

Lottery.com, Inc. appoints new Chairman and additional Board directors

Retrieved on: 
Thursday, November 10, 2022

AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lottery.com, Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or the “Company”), a global tech company delivering trusted gaming solutions wherever lotteries are played, announces the appointment of an existing director, Matthew Howard McGahan as Chairman of the Board. This announcement comes at a transformational time for the Company.

Key Points: 
  • After graduating from Guildford Engineering Technology College, he joined his familys business, Pinewood Motor Group, which was founded in 1969.
  • Matthew also founded Magic Automotive Group which developed into one of the largest Harley-Davidson and BMW dealerships in Europe.
  • Matthew McGahan, Chairman, Lottery.com, said, My appointment as Chairman comes at an important inflection point for the Company.
  • Sohail Quraeshi, CEO, commented, I would like to welcome all the new directors to the Board, and am delighted at Matthews appointment to Chairman.